Cleveland BioLabs (CBLI) -24.3% premarket after announcing BARDA has declined to invite...

|About: Cleveland BioLabs, Inc. (CBLI)|By:, SA News Editor

Cleveland BioLabs (CBLI) -24.3% premarket after announcing BARDA has declined to invite submission of a full proposal for continued development funding of CBLB502 as a drug candidate to protect healthy tissues from acute stresses such as radiation and chemotherapy.